Black Diamond Therapeutics

Compare

1,552 Followers

BDTX Stock Chart & Stats

$3.89

-$0.07(-3.30%)

At close: Jan 08 4:00 PM EST

$3.89

-$0.07(-3.30%)

Day’s Range― - ―

52-Week Range$1.20 - $4.45

Previous CloseN/A

Volume170.82K

Average Volume (3M)985.21K

Market Cap

$221.48M

Enterprise Value$18.80M

Total Cash (Recent Filing)$29.99M

Total Debt (Recent Filing)$16.97M

Price to Earnings (P/E)16.4

Beta2.11

Next Earnings

Nov 10, 2025

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding56,935,280

10 Day Avg. Volume811,713

30 Day Avg. Volume985,205

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.08

Enterprise Value/Revenue0.27

Enterprise Value/Gross Profit0.27

Enterprise Value/Ebitda3.79

Forecast

1Y Price Target

$8.60

Price Target Upside121.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentThe drug silevertinib (BDTX-1535) has a mechanism of action that targets a broad range of EGFR mutations while sparing wild-type EGFR, making it a promising treatment for NSCLC.

Financial PerformanceA full-year 2025 net gain of $0.33 is now projected, compared to the prior net loss estimate of $1.32 per share.

Market PotentialUpcoming Phase 2 catalysts in 1L NSCLC could significantly boost the stock's value and make Black Diamond a potential M&A candidate.

Bears Say

Black Diamond Therapeutics News

Black Diamond Therapeutics resumed with a Buy at Stifel

Stifel analyst Laura Prendergast resumed coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $8 price...

14d ago

BDTX

Black Diamond Therapeutics initiated with a Buy at Freedom Capital

Freedom Capital initiated coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $6 price target Lead...

29d ago

BDTX

Black Diamond, TransMedics, Duolingo, AT&T, Coherus: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($BDTX) ), ( ($TMDX) ), ( ($DUOL) ), ( ($T)...

2M ago

BDTX

Black Diamond Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $8 price target The firm...

2M ago

BDTX

Black Diamond Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Brad Canino initiated coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $8 price...

2M ago

BDTX

Black Diamond price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $10 from...

3M ago

BDTX

Black Diamond Therapeutics Reports Strong Financial Turnaround

Black Diamond Therapeutics, Inc. ( ($BDTX) ) has released its Q2 earnings. Here is a breakdown of the...

3M ago

BDTX

Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)

“With enrollment completed in our silevertinib Phase 2 trial for the treatment of newly diagnosed patients with EGFRm...

3M ago

BDTX

Black Diamond Therapeutics sees cash runway into 4Q27

Black Diamond ended the second quarter of 2025 with approximately $142.8 million in cash, cash equivalents and investments,...

3M ago

BDTX

Black Diamond, Nike, Apple, Block, IonQ: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($BDTX) ), ( ($NKE) ), ( ($AAPL) ), ( ($XYZ)...

4M ago

NKE

XYZ

Optimistic Buy Rating for Black Diamond Therapeutics: Promising BDTX-1535 Drug and Strong Financial Position

Black Diamond Therapeutics (BDTX) has received a new Buy rating, initiated by Raymond James analyst, Sean McCutcheon. Sean...

4M ago

BDTX

Black Diamond Therapeutics resumed with an Outperform at Raymond James

Raymond James resumed coverage of Black Diamond Therapeutics (BDTX) with an Outperform rating and $11 price target BDTX-1535...

4M ago

BDTX

Black Diamond’s 2025 Annual Stockholders Meeting Highlights

An update from Black Diamond Therapeutics ( ($BDTX) ) is now available. On June 12, 2025, Black Diamond...

5M ago

BDTX

Black Diamond Therapeutics Reports Strong Q1 2025 Earnings

Black Diamond Therapeutics, Inc. ( ($BDTX) ) has released its Q1 earnings. Here is a breakdown of the...

5M ago

BDTX

BDTX FAQ

What was Black Diamond Therapeutics’s price range in the past 12 months?

Black Diamond Therapeutics lowest stock price was $1.20 and its highest was $4.45 in the past 12 months.

What is Black Diamond Therapeutics’s market cap?

Black Diamond Therapeutics’s market cap is $221.48M.

When is Black Diamond Therapeutics’s upcoming earnings report date?

Black Diamond Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 11 days.

How were Black Diamond Therapeutics’s earnings last quarter?

Black Diamond Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.058.

Is Black Diamond Therapeutics overvalued?

According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Black Diamond Therapeutics pay dividends?

Black Diamond Therapeutics does not currently pay dividends.

What is Black Diamond Therapeutics’s EPS estimate?

Black Diamond Therapeutics’s EPS estimate is -0.23.

How many shares outstanding does Black Diamond Therapeutics have?

Black Diamond Therapeutics has 56,935,280 shares outstanding.

What happened to Black Diamond Therapeutics’s price movement after its last earnings report?

Black Diamond Therapeutics reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went down -15.242%.

Which hedge fund is a major shareholder of Black Diamond Therapeutics?

Currently, no hedge funds are holding shares in BDTX

Black Diamond Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

11.85%

Trailing 12-Months

Asset Growth

10.93%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics (BDTX) Earnings & Revenues

Historic Earnings Reports

BDTX Stock 12 Month Forecast

Average Price Target

$8.60

▲(121.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,4.28,4.84,5.4,5.96,6.52,7.08,7.64,8.2,8.76,9.32,9.879999999999999,10.44,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,4.095384615384615,4.470769230769231,4.846153846153847,5.2215384615384615,5.596923076923076,5.972307692307693,6.3476923076923075,6.723076923076922,7.098461538461538,7.473846153846154,7.849230769230768,8.224615384615385,{"y":8.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.72,3.8953846153846157,4.070769230769231,4.246153846153846,4.421538461538462,4.596923076923077,4.772307692307693,4.947692307692307,5.123076923076923,5.298461538461538,5.473846153846154,5.649230769230769,5.8246153846153845,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.78,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >